Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 49

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 49
---
 of $10.2 million and $18.6 million, respectively,
and used $10.3 million and $18.9 million, respectively, to fund operations. As of September 30, 2025, we have incurred approximately
$419 million of cumulative net losses. As of September 30, 2025 and December 31, 2024, we had cash and cash equivalents of $5.3 million
and $5.9 million, respectively.

We
have substantial future capital requirements, including to continue our research and development activities and advance our drug candidates
through various development stages, including the Phase 3 registrational trial of IMNN-001 in advanced ovarian cancer. We are unable
to estimate the duration and completion costs of our research and development projects or when, if ever, and to what extent we will receive
cash inflows from the commercialization and sale of a product. Our inability to complete any of our research and development activities,
preclinical studies or clinical trials in a timely manner or our failure to enter into collaborative agreements when appropriate could
significantly increase our capital requirements and could adversely impact our liquidity. While our estimated future capital requirements
are uncertain and could increase or decrease as a result of many factors, including the extent to which we choose to advance our research,
development activities, preclinical studies and clinical trials, or if we are in a position to pursue manufacturing or commercialization
activities, we will need significant additional capital to develop our drug candidates through development and clinical trials, obtain
regulatory approvals and manufacture and commercialize approved products, if any. We do not know whether we will be able to access additional
capital when needed or on terms favorable to us or our stockholders. Our inability to raise additional capital, or to do so on terms
reasonably acceptable to us, would jeopardize the future success of our business.

Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item
3. Defaults Upon Senior Securities.

None.

Item
4. Mine Safety Disclosures.

Not
applicable.

Item
5. Other Information.

During
the quarter ended September 30, 2025, no directors or executive officers entered into, modified or terminated, contracts, instructions
or written plans for the sale or purchase of the Company’s securities that were intended to satisfy the affirmative defense conditions
of Rule 10b5-1.

Item
6. Exhibits. 

    31.1+
    Certification of Chief